EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Terminated
1
100.0%
No approval data available
- Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center. - UCLA researchers found that early radiation therapy side effects in prostate cancer patients may indicate higher risks of serious long-term urinary and bowel complications. - Vanderbilt researchers discovered that the inherited mutated WNT9B gene, crucial in embryonic prostate development, increases adult prostate cancer risk.
- EDAP TMS SA has initiated a Phase I/II trial (PULS) using High Intensity Focused Ultrasound (HIFU) for pancreatic tumor treatment. - The first patient with locally advanced pancreatic cancer was treated successfully in the PULS trial, showing tolerance to the HIFU intervention. - The PULS trial aims to evaluate both the tolerance and preliminary efficacy of intraoperative HIFU for unresectable pancreatic tumors. - This milestone reflects EDAP's commitment to innovative therapies for areas of significant unmet medical need, like pancreatic cancer.
- EDAP TMS has initiated a Phase I/II clinical trial evaluating Focal One robotic HIFU for benign prostatic hyperplasia (BPH) treatment. - The study aims to determine optimal treatment parameters using Focal One HIFU to improve BPH symptoms with minimal side effects. - The trial is a prospective, multicenter study conducted in two parts, starting in France and potentially expanding to the United States. - Focal One's precision in delivering HIFU energy is expected to offer a less invasive BPH treatment option, preserving urethral integrity.
